KR20050070103A - 캄프토테신의 고분자량 유도체 - Google Patents
캄프토테신의 고분자량 유도체 Download PDFInfo
- Publication number
- KR20050070103A KR20050070103A KR1020057007500A KR20057007500A KR20050070103A KR 20050070103 A KR20050070103 A KR 20050070103A KR 1020057007500 A KR1020057007500 A KR 1020057007500A KR 20057007500 A KR20057007500 A KR 20057007500A KR 20050070103 A KR20050070103 A KR 20050070103A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- camptothecin
- molecular weight
- substituent
- high molecular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polyamides (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (11)
- 폴리에틸렌글리콜과 측쇄에 카르복실릭산기를 갖는 폴리머의 공중합체의 카르복실릭산기가 에스테르 결합을 통해서 페놀성 캄프토테신의 페놀성 히드록실기와 결합되어 있는 구조를 갖는 캄프토테신의 고분자량 유도체.
- 제1항에 있어서, 폴리에틸렌글리콜과 측쇄에 카르복실릭산기를 갖는 폴리머의 공중합체가 폴리에틸렌글리콜과 측쇄에 카르복실릭산기를 갖는 폴리머의 블록공중합체인, 캄프토테신의 고분자량 유도체.
- 제1항 또는 제2항에 있어서, 측쇄에 카르복실릭산기를 갖는 폴리머가 산성 아미노산 폴리머인, 캄프토테신의 고분자량 유도체.
- 제3항에 있어서, 산성 아미노산 폴리머가 폴리글루타민산 또는 폴리아스파라긴산인, 캄프토테신의 고분자량 유도체.
- 일반식(I)의 캄프토테신의 고분자량 유도체:[여기서, R1은 수소원자 또는 선택적으로 치환기를 갖는 (C1 내지 C6)알킬기를 나타내고, t는 5 내지 11500의 정수를 나타내고, A는 결합기를 나타내고, d+e+f는 3 내지 200의 정수를 나타내고, R2는 수소원자 또는 선택적으로 치환기를 갖는 (C1 내지 C6)알킬기 또는 선택적으로 치환기를 갖는 실릴기를 나타내고, R3는 수소 원자 또는 선택적으로 치환기를 갖는 (C1 내지 C6)알킬기를 나타내고, R4는 동일하거나 다르며, 선택적으로 치환기를 갖는 (C1 내지 C20)알콕실기, 선택적으로 치환기를 갖는 (C1 내지 C20)알킬아미노기, 선택적으로 치환기를 갖는 디(C1 내지 C20)알킬아미노기 또는 선택적으로 치환기를 갖는 (C1 내지 C20)알킬아미노카르보닐 (C1 내지 C20)알킬아미노기를 나타내고, P는 수소원자, (C1 내지 C6)아실기 또는 (C1 내지 C6)알콕시카르보닐기를 나타낸다].
- 제5항에 있어서, R1이 선택적으로 치환기를 갖는 (C1 내지 C4)알킬기를 나타내고, t는 100 내지 300의 정수이고, A는 (C2 내지 C6)알킬렌기이고, d+e+f는 6 내지 60의 정수이고, d+e+f를 기준으로 d의 비율이 0 내지 60%이고, e의 비율이 0 내지 60%이고, f의 비율이 1 내지 100%이고, R2는 수소원자 또는 선택적으로 치환기를 갖는 (C1 내지 C4)알킬기이고, R3는 수소원자 또는 치환기를 갖지 않는 (C1 내지 C4)알킬기이고, R4는 R4는 동일하거나 다르며, 선택적으로 치환기를 갖는 (C1 내지 C8)알콕실기, 선택적으로 치환기를 갖는 (C1 내지 C8)알킬아미노기, 선택적으로 치환기를 갖는 디(C1 내지 C8)알킬아미노기 또는 선택적으로 치환기를 갖는 (C1 내지 C8)알킬아미노카르보닐 (C1 내지 C8)알킬아미노기를 나타내고, P는 (C2 내지 C4)아실기를 나타내는, 캄프토테신의 고분자량 유도체.
- 제6항에 있어서, R1이 메틸기이고, A는 트리메틸렌기이고, R2는 수소원자이고, R3는 디메틸아미노메틸기이고, R4는 이소프로필아미노카르보닐이소프로필아미노기이며, P는 아세틸기인, 캄프토테신의 고분자량 유도체.
- 제6항에 있어서, R1이 메틸기이고, A는 트리메틸렌기이고, R2는 에틸기이고, R3는 수소원자이고, R4는 이소프로필아미노카르보닐이소프로필아미노기이며, P는 아세틸기인, 캄프토테신의 고분자량 유도체.
- 폴리에틸렌글리콜 부분과 폴리아미노글루타민산 또는 폴리아스파라긴산의 블록공중합체와 페놀성 캄프토테신을, 유기용제중에서 축합제를 사용하여 반응시킴에 의해 수득되는, 캄프토테신의 고분자량 유도체.
- 폴리에틸렌글리콜과 측쇄에 카르복실릭산기를 갖는 폴리머의 공중합체의 카르복실릭산기를, 축합제를 사용하여 에스테르 결합을 통해서 페놀성 캄프토테신의 페놀성 히드록실기와 결합시킴을 포함하는, 제1항 내지 제8항중 어느 한항에 기재된 캄프토테신의 고분자량 유도체의 제조방법.
- 제1항 내지 제9항중 어느 한항에 기재된 캄프토테신의 고분자량 유도체를 함유하는 항암제.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2002-00316942 | 2002-10-31 | ||
JP2002316942 | 2002-10-31 | ||
PCT/JP2003/013838 WO2004039869A1 (ja) | 2002-10-31 | 2003-10-29 | カンプトテシン類の高分子誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050070103A true KR20050070103A (ko) | 2005-07-05 |
KR101057102B1 KR101057102B1 (ko) | 2011-08-16 |
Family
ID=32211705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057007500A KR101057102B1 (ko) | 2002-10-31 | 2003-10-29 | 캄프토테신의 고분자량 유도체 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7495099B2 (ko) |
EP (1) | EP1580216B1 (ko) |
JP (1) | JP4745664B2 (ko) |
KR (1) | KR101057102B1 (ko) |
CN (1) | CN1309763C (ko) |
AU (1) | AU2003280592B2 (ko) |
CA (1) | CA2502870C (ko) |
DK (1) | DK1580216T3 (ko) |
ES (1) | ES2488841T3 (ko) |
PT (1) | PT1580216E (ko) |
RU (1) | RU2315782C2 (ko) |
TW (1) | TW200418906A (ko) |
WO (1) | WO2004039869A1 (ko) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100475269C (zh) * | 2002-03-05 | 2009-04-08 | 北京键凯科技有限公司 | 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途 |
ES2291620T3 (es) | 2002-03-13 | 2008-03-01 | Beijing Jiankai Technology Co., Ltd. | Derivado de polimeros hidrfilicos con rama tipo y y metodo de preparacion de compuesto metodo que comprende el compuesto anterior. |
ATE533513T1 (de) | 2002-09-06 | 2011-12-15 | Cerulean Pharma Inc | Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel |
KR101203475B1 (ko) * | 2004-09-22 | 2012-11-21 | 니폰 가야꾸 가부시끼가이샤 | 신규 블록 공중합체, 미셀 제제물 및 이를 유효성분으로함유하는 항암제 |
DE602006007177D1 (de) | 2005-12-05 | 2009-07-16 | Nitto Denko Corp | Polyglutamat-aminosäure-konjugate und verfahren |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
JP5181347B2 (ja) | 2006-05-18 | 2013-04-10 | 日本化薬株式会社 | ポドフィロトキシン類の高分子結合体 |
WO2008010463A1 (fr) | 2006-07-19 | 2008-01-24 | Nippon Kayaku Kabushiki Kaisha | Conjugué polymère d'une combrétastatine |
JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
WO2008056596A1 (en) | 2006-11-06 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
WO2008056654A1 (en) | 2006-11-08 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
EP2155255B1 (en) | 2007-05-09 | 2013-08-14 | Nitto Denko Corporation | Compositions that include a hydrophobic compound and a polyamino acid conjugate |
EP2206502B1 (en) * | 2007-09-28 | 2018-09-12 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of steroid |
CN104096236A (zh) * | 2008-03-06 | 2014-10-15 | 日东电工株式会社 | 用于治疗癌症的聚合物紫杉醇结合物和方法 |
CN101977631A (zh) * | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
EP2284209B1 (en) * | 2008-05-08 | 2016-08-31 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
AU2009250393B2 (en) | 2008-05-23 | 2013-09-19 | Nanocarrier Co., Ltd. | Polymer derivative of Docetaxel, method of preparing the same and uses thereof |
JP2011162569A (ja) | 2008-05-23 | 2011-08-25 | Nano Career Kk | カンプトテシン高分子誘導体及びその用途 |
WO2010083154A2 (en) * | 2009-01-13 | 2010-07-22 | The Uab Research Foundation | Heterofunctional segment-poly(ethylene glycol) polymers as delivery vehicles |
JP2012526049A (ja) * | 2009-05-04 | 2012-10-25 | インテザイン テクノロジーズ, インコーポレイテッド | 腫瘍治療のためのsn−38を含有するポリマーミセル |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
ES2641233T3 (es) | 2009-10-21 | 2017-11-08 | Nippon Kayaku Kabushiki Kaisha | Copolímero en bloque para su administración intraperitoneal que contiene un agente antineoplásico, preparación micelar del mismo y agente oncoterapéutico que comprende la preparación micelar como principio activo |
JP2011225510A (ja) * | 2010-04-01 | 2011-11-10 | National Cancer Center | 新規な抗腫瘍剤 |
WO2012067138A1 (ja) | 2010-11-17 | 2012-05-24 | 日本化薬株式会社 | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
JP5711378B2 (ja) | 2011-09-11 | 2015-04-30 | 日本化薬株式会社 | ブロック共重合体の製造方法 |
US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
EP2918292B1 (en) * | 2012-11-08 | 2019-12-11 | Nippon Kayaku Kabushiki Kaisha | Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same |
TWI716342B (zh) | 2013-10-04 | 2021-01-21 | 美商普洛林克斯有限責任公司 | Sn-38之緩釋結合物 |
WO2015125640A1 (ja) * | 2014-02-19 | 2015-08-27 | 日本化薬株式会社 | カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途 |
JP6461088B2 (ja) * | 2014-02-19 | 2019-01-30 | 日本化薬株式会社 | 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物 |
KR20170095811A (ko) * | 2014-12-26 | 2017-08-23 | 니폰 가야꾸 가부시끼가이샤 | 캄프토테신류 고분자 유도체의 의약 제제 |
JP2016124818A (ja) * | 2014-12-26 | 2016-07-11 | 日本化薬株式会社 | 転移性肝癌治療薬及び転移性肝癌の治療方法 |
KR20170120568A (ko) * | 2015-02-23 | 2017-10-31 | 니폰 가야꾸 가부시끼가이샤 | 생리활성물질결합 블록 공중합체 |
RU2695357C1 (ru) | 2015-06-24 | 2019-07-23 | Ниппон Каяку Кабусики Каися | Новый комплекс платины (iv) |
JP6735759B2 (ja) | 2015-09-03 | 2020-08-05 | 日本化薬株式会社 | カンプトテシン類高分子誘導体を含有する医薬組成物 |
AU2016324370B2 (en) | 2015-09-14 | 2021-02-25 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of hexa-coordinated platinum complex |
US11026889B2 (en) * | 2015-12-09 | 2021-06-08 | Board Of Regents, The University Of Texas System | Polymeric drug delivery systems for treatment of disease |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
US10946028B2 (en) | 2015-12-22 | 2021-03-16 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex |
EP3424513A4 (en) * | 2016-03-01 | 2019-10-23 | Nippon Kayaku Kabushiki Kaisha | PHARMACEUTICAL PREPARATION WITH CAMPTOTHECINOUS POLYMER DERIVATIVE |
EP3492512A4 (en) | 2016-07-30 | 2020-04-08 | Nippon Kayaku Kabushiki Kaisha | NEW POLYMER DERIVATIVES, AND NEW POLYMER DERIVATIVE IMAGING PROBE USING SAID NEW POLYMER DERIVATIVES |
EP3495406A4 (en) | 2016-08-02 | 2020-04-01 | Nippon Kayaku Kabushiki Kaisha | ACTIVE TARGETING TYPE POLYMER DERIVATIVE, COMPOSITION CONTAINING SAID POLYMER DERIVATIVE, AND USES OF SAID POLYMER DERIVATIVE AND COMPOSITION THEREOF |
CN106496542B (zh) * | 2016-09-23 | 2018-06-22 | 天津科技大学 | 谷胱甘肽敏感的两亲性聚乙二醇-羟基喜树碱偶联物 |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
EP3645530A2 (en) | 2017-06-30 | 2020-05-06 | Massachusetts Institute of Technology | Branched multi-functional macromonomers and related polymers and uses thereof |
WO2019140271A2 (en) | 2018-01-12 | 2019-07-18 | Prolynx Llc | Synergistic cancer treatment |
WO2020037236A1 (en) | 2018-08-17 | 2020-02-20 | Massachusetts Institute Of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
KR20220010525A (ko) | 2019-05-20 | 2022-01-25 | 메사추세츠 인스티튜트 오브 테크놀로지 | 보론산 에스테르 전구약물 및 그의 용도 |
US20210220391A1 (en) | 2020-01-10 | 2021-07-22 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5839683A (ja) * | 1981-09-04 | 1983-03-08 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
JPS6247193A (ja) | 1985-08-26 | 1987-02-28 | 内橋エステック株式会社 | 電子部品のはんだ付方法 |
JP2517760B2 (ja) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
JP3310000B2 (ja) * | 1990-11-07 | 2002-07-29 | 靖久 桜井 | 水溶性高分子抗癌剤及び薬物担持用担体 |
JPH05117385A (ja) | 1991-10-31 | 1993-05-14 | Res Dev Corp Of Japan | ブロツク共重合体の製造法、ブロツク共重合体及び水溶性高分子抗癌剤 |
JP3270592B2 (ja) * | 1992-10-26 | 2002-04-02 | 日本化薬株式会社 | ブロック共重合体−抗癌剤複合体医薬製剤 |
JP3268913B2 (ja) * | 1992-10-27 | 2002-03-25 | 日本化薬株式会社 | 高分子担体 |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
JP2694923B2 (ja) | 1995-08-21 | 1997-12-24 | 科学技術振興事業団 | 水溶性高分子化医薬製剤 |
US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6207832B1 (en) | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
RU2002128610A (ru) | 2000-03-17 | 2004-03-27 | Селл Терапьютикс, Инк. (Us) | Композиция конъюгатов полиглутаминовой кислоты с камптотецином (варианты) и способ ее получения (варианты), фармацевтическая композиция (варианты) и способ лечения лейкоза или плотной опухоли |
EP1292709B1 (en) * | 2000-06-02 | 2012-01-18 | Eidgenössische Technische Hochschule Zürich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
DE60235812D1 (de) | 2001-06-20 | 2010-05-12 | Nippon Kayaku Kk | Blockcopolymer mit verringertem verunreinigungsgehalt, polymerer träger, pharmazeutische zubereitungen in polymerer form und verfahren zur herstellung davon |
JP2003342168A (ja) * | 2002-05-24 | 2003-12-03 | Nano Career Kk | 注射用薬物含有ポリマーミセル製剤の製造方法 |
JP2003342167A (ja) * | 2002-05-24 | 2003-12-03 | Nano Career Kk | カンプトテシン誘導体の製剤およびその調製方法 |
EP1594482A1 (en) * | 2003-03-26 | 2005-11-16 | LTT Bio-Pharma Co., Ltd. | Intravenous nanoparticles for targeting drug delivery and sustained drug release |
JP5000512B2 (ja) * | 2005-05-11 | 2012-08-15 | 日本化薬株式会社 | シチジン系代謝拮抗剤の高分子誘導体 |
-
2003
- 2003-10-29 CN CNB2003801025487A patent/CN1309763C/zh not_active Expired - Fee Related
- 2003-10-29 PT PT37699493T patent/PT1580216E/pt unknown
- 2003-10-29 RU RU2005116309/04A patent/RU2315782C2/ru active
- 2003-10-29 KR KR1020057007500A patent/KR101057102B1/ko active IP Right Grant
- 2003-10-29 CA CA2502870A patent/CA2502870C/en not_active Expired - Fee Related
- 2003-10-29 WO PCT/JP2003/013838 patent/WO2004039869A1/ja active Application Filing
- 2003-10-29 DK DK03769949.3T patent/DK1580216T3/da active
- 2003-10-29 ES ES03769949.3T patent/ES2488841T3/es not_active Expired - Lifetime
- 2003-10-29 AU AU2003280592A patent/AU2003280592B2/en not_active Ceased
- 2003-10-29 US US10/532,670 patent/US7495099B2/en active Active
- 2003-10-29 JP JP2004548065A patent/JP4745664B2/ja not_active Expired - Fee Related
- 2003-10-29 EP EP03769949.3A patent/EP1580216B1/en not_active Expired - Lifetime
- 2003-10-30 TW TW092130275A patent/TW200418906A/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2004039869A1 (ja) | 2004-05-13 |
EP1580216B1 (en) | 2014-05-14 |
CN1309763C (zh) | 2007-04-11 |
US7495099B2 (en) | 2009-02-24 |
EP1580216A1 (en) | 2005-09-28 |
CA2502870A1 (en) | 2004-05-13 |
US20060067910A1 (en) | 2006-03-30 |
JPWO2004039869A1 (ja) | 2006-03-02 |
AU2003280592A1 (en) | 2004-05-25 |
TW200418906A (en) | 2004-10-01 |
EP1580216A4 (en) | 2008-10-29 |
DK1580216T3 (da) | 2014-08-18 |
RU2315782C2 (ru) | 2008-01-27 |
CN1708540A (zh) | 2005-12-14 |
ES2488841T3 (es) | 2014-08-29 |
TWI305538B (ko) | 2009-01-21 |
PT1580216E (pt) | 2014-07-31 |
AU2003280592B2 (en) | 2008-12-18 |
CA2502870C (en) | 2011-07-26 |
JP4745664B2 (ja) | 2011-08-10 |
KR101057102B1 (ko) | 2011-08-16 |
RU2005116309A (ru) | 2006-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101057102B1 (ko) | 캄프토테신의 고분자량 유도체 | |
US8323669B2 (en) | Polymer conjugate of taxane | |
JP5008783B2 (ja) | 高分子量のポリマーを基剤とするプロドラッグ | |
EP2258397B1 (en) | Polymer conjugate of physiologically active substance | |
US8940332B2 (en) | High-molecular weight conjugate of podophyllotoxins | |
EP0673258B1 (en) | Polymer-bound camptothecin derivatives | |
EP2042195A1 (en) | Polymer conjugate of combretastatin | |
USRE46190E1 (en) | High-molecular weight conjugate of steroids | |
JP6223995B2 (ja) | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 | |
KR0169195B1 (ko) | PVMA-Ara-C 결합체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140508 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150716 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160720 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170719 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180718 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190718 Year of fee payment: 9 |